Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POMEROL trial
2023-508242-18-00Phase 4Authorised
- Sponsor
- GETAID
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 4, randomised trial of infliximab in Crohn's disease (2 arms), sponsored by GETAID. Primary endpoint: Treatment success at 12 months. Planned start Nov 2023; status: authorised.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-508242-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508242-18-00.